ZB-106, also known as tibulizumab, is a tetravalent, bispecific antibody with dual antagonist activity against IL-17A and BAFF (B-cell activating factor).
Zura Bio holds an exclusive worldwide license for the development and commercialization in identified indications.
ZB-106 has completed Phase 1 studies in healthy volunteers and is progressing the program in immunological disorders with high unmet need.
Anti IL-17A / BAFF (BAFFx17)
ZB-106 Disrupts IL-17A and/or BAFF-Mediated Inflammation
ZB-106 has the potential to treat diseases driven by B-cell and T-cell signalings
T-cell and B-cell synergy
Multiple T-cell driven diseases remain sub-optimally treated despite the growth in “pure play” anti-IL-17A drugs
B-cell driven diseases often have a T-cell driven autoimmune component contributing to the pathology
Combined approach to address T-cell and B-cell drivers of autoimmunity has the potential to increase clinical benefit
1. Liu et al. 2016. J Inflam Research
2. Manetta et al. 2014. J Inflam Research
3. Benschop et al. 2019. Mabs
4. Smulski and Eibel. 2018. FrontImmunol